<DOC>
	<DOCNO>NCT00563849</DOCNO>
	<brief_summary>To determine efficacy safety combination leflunomide methotrexate treat active rheumatoid arthritis ( RA ) open noncomparative multicenter trial .</brief_summary>
	<brief_title>Leflunomide + Methotrexate Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Male female age 18 75 year old . Female subject must nonchildbearing potential ( i.e. , surgically sterile least 2 year postmenopausal ) OR participation contingent upon follow : They practice medically accept contraceptive regimen ( acceptable method must include one follow : systemic contraceptive , oral implant estrogen/progestin ; diaphragm intravaginal spermicide ; cervical cap ; intrauterine device ; condom intravaginal spermicide ) AND demonstrate pregnant ( serum pregnancy test ) breastfeeding time study entry AND intend continue contraceptive regimen remain pregnant throughout study AND willing undergo pregnancy test ( serum ) screening ( urine ) monthly thereafter AND fully inform risk enter trial provide write consent enter trial ; female patient sexually active also adequately informed appropriate method contraception AND agree get pregnant 24 month discontinuation treatment study medication undergo washout procedure cholestyramine charcoal . Male subject must consent practice contraception study . The subject need clinically diagnose rheumatoid arthritis include diagnosis RA ACR criterion great = 6 month prior enrollment active disease ACR criterion . Men wish father child consider discontinue use study drug take cholestyramine 8 gm 3 time daily 11 day . In addition , male consider discontinuation methotrexate treatment wait additional three month . Active disease ACR criterion despite methotrexate therapy three follow four criterion : great = 9 tender joint great = 6 swollen joint great = 45 minute morning stiffness ESR great = 28mm/hr Subject must remain unchanged dos NSAIDs least 4 week prior study drug administration throughout timecourse study . Concomitant therapy permit corticosteroid dose less = 10 mg prednisone daily ( steroid equivalent administer orally ) , provide dose stable least 4 week prior study drug administration ; dose must remain constant throughout timecourse study . Subjects must receive intramuscular , intraarticular intravenous corticosteroid within 4 week prior initiate study participation study . Subjects must able willing comply term protocol . Informed consent must obtain subject enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>